Vanda Pharmaceuticals Inc.
VNDA
$8.81
-$0.48-5.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,066.53% | -413.78% | -512.58% | -805.05% | -853.29% |
| Total Depreciation and Amortization | 21.61% | 32.49% | 62.02% | 109.42% | 225.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 92,760.20% | -221.76% | -924.34% | -234.72% | -101.22% |
| Change in Net Operating Assets | 226.68% | 234.65% | 381.37% | 2.27% | -777.91% |
| Cash from Operations | -594.56% | -363.12% | -1,160.40% | -393.95% | -223.09% |
| Capital Expenditure | 78.85% | 98.95% | 98.95% | 97.64% | 95.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 854.13% | 37.00% | -27.72% | 141.40% | -114.28% |
| Cash from Investing | 644.23% | 182.79% | 206.55% | 120.54% | -44.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,184.52% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,774.84% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 114.11% | -205.29% | 5,000.00% | -733.33% | -446.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.87% | 63.15% | 53.33% | 94.17% | -4,330.43% |